Date: 2015-10-26
Type of information: Development agreement
Compound: next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics
Company: Ipsen (France) EpiVax (USA - RI)
Therapeutic area: undisclosed
Type agreement: collaboration R&D development
Action mechanism:
Disease:
Details: * On October 26, 2015, Ipsen and EpiVax announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics. Ipsen is actively developing an innovative platform of novel neurotoxin derived therapeutics, including TSI, that is opening up new therapeutic opportunities to address various medical conditions with unmet need. EpiVax will move the program forward, continuing potential product development for clinical use in neuromuscular health and aesthetic treatments. EpiVax will present the results of the research program so far conducted at the upcoming IBRCC 2015 conference on botulinum neurotoxins, in Frederick Maryland. EpiVax applied its proprietary T cell epitope modification technology “ISPRI” to generate an engineered BoNT sequence. This platform program employs two key technologies developed and perfected by EpiVax: deimmunization and tolerization.
Financial terms:
Latest news:
